MDM2 and glioblastoma: A dual MDM2/4 inhibitor, RS3594, and a CXCR4 antagonist, AMD3100, were used to treat human GBM cells and GBM stem-like cells and in addition to inhibiting neurosphere growth and inducing differentiation of GBM cells, AMD3100 and RS3594 demonstrated synergistic effects on cancer stem components (Daniele et al., 2021).